Inozyme Pharma to Present at Upcoming Investor Conferences

Core Insights - Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases affecting bone health and blood vessel function [3][4] - The company will have presentations at two upcoming investor conferences, the Stifel 2024 Healthcare Conference and the Jefferies London Healthcare Conference [1][2] Company Overview - Inozyme Pharma specializes in the PPi-Adenosine Pathway, which involves the ENPP1 enzyme that generates inorganic pyrophosphate (PPi) and adenosine, both crucial for regulating mineralization and controlling smooth muscle cell proliferation in blood vessels [3] - Disruptions in this pathway can lead to severe conditions such as ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL) [3] Lead Candidate - The lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) aimed at increasing PPi and adenosine levels [4] - INZ-701 is currently in clinical development for treating ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, targeting the underlying issues of pathological mineralization and intimal proliferation [4]